Clinical trials: A transparent future for clinical trial reporting

Nature Reviews Rheumatology

Volumn 11, Issue 6, 2015, Pages 324-326

  Karassa, Fotini B ^a   Ioannidis, John P A ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; SECUKINUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG COST; FOOD AND DRUG ADMINISTRATION; FUNDING; GOVERNMENT; HUMAN; INFLAMMATORY DISEASE; NOTE; PRIORITY JOURNAL; PSORIASIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; FACTUAL DATABASE; LEGISLATION AND JURISPRUDENCE;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; REGISTRIES;

EID: 84930379178     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.65     Document Type: Note

References (10)

1. US Food and Drug Administration. Food and Drug Administration Amendments Act of 2007. Public Law 110-85 [online], http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/Foodand DrugAdministrationAmendmentsActof2007/FullTextofFDAAALaw/default.htm (2007).
2. Anderson, M. L. et al. Compliance with results reporting at ClinicalTrials.gov. N. Engl. J. Med. 372, 1031-1039 (2015).
3. Prayle, A. P., Hurley, M. N. & Smyth, A. R. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ 344, d7373 (2012).
4. Law, M. R., Kawasumi, Y. & Morgan, S. G. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Aff. (Millwood) 30, 2338-2345 (2011).
5. Saito, H. & Gill, C. J. How frequently do the results from completed US clinical trials enter the public domain-A statistical analysis of the ClinicalTrials.gov database. PLoS ONE 9, e101826 (2014).
6. Ioannidis, J. P. & Karassa, F. B. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ 341, c4875 (2010).
7. Ioannidis, J. P., Karassa, F. B., Druyts, E., Thorlund, K. & Mills, E. J. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat. Rev. Rheumatol. 9, 665-673 (2013).
8. Khan, N. A., Lombeida, J. I., Singh, M., Spencer, H. J. & Torralba, K. D. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. Arthritis Rheum. 64, 2059-2067 (2012).
9. Goodman, S. N. Clinical trial data sharing: what do we do now? Ann. Intern. Med. 162, 308-309 (2015).
10. Flacco, M. E. et al. Head to head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J. Clin. Epidemiol. http://dx.doi.org/10.1016/j.jclinepi.2014.12.016 (2015).